Quotient Limited (NASDAQ:QTNT – Get Rating) Director Prondzynski Heino Von purchased 700,000 shares of Quotient stock in a transaction dated Thursday, September 15th. The shares were acquired at an average cost of $0.20 per share, with a total value of $140,000.00. Following the transaction, the director now directly owns 1,405,879 shares in the company, valued at $281,175.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Prondzynski Heino Von also recently made the following trade(s):
Get
Quotient alerts:
- On Tuesday, September 13th, Prondzynski Heino Von purchased 100,000 shares of Quotient stock. The shares were acquired at an average cost of $0.18 per share, with a total value of $18,000.00.
- On Tuesday, September 6th, Prondzynski Heino Von purchased 100,000 shares of Quotient stock. The shares were acquired at an average cost of $0.17 per share, with a total value of $17,000.00.
Quotient Stock Performance
NASDAQ:QTNT opened at $0.21 on Friday. The stock's fifty day moving average is $0.23 and its 200 day moving average is $0.51. Quotient Limited has a fifty-two week low of $0.16 and a fifty-two week high of $3.19. The firm has a market capitalization of $21.58 million, a PE ratio of -0.16 and a beta of 2.76.
Quotient (NASDAQ:QTNT – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The company had revenue of $8.81 million during the quarter, compared to the consensus estimate of $9.40 million. Equities analysts forecast that Quotient Limited will post -0.69 EPS for the current year.
Analyst Upgrades and Downgrades
QTNT has been the subject of several analyst reports. Cowen reduced their target price on shares of Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a report on Wednesday, June 29th. StockNews.com began coverage on Quotient in a research note on Saturday. They issued a "hold" rating for the company. BTIG Research lowered their target price on Quotient from $9.00 to $1.50 and set a "buy" rating for the company in a research report on Wednesday, June 29th. Finally, Cowen lowered their target price on Quotient from $9.00 to $3.00 and set an "outperform" rating for the company in a research report on Wednesday, June 29th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $2.25.
Institutional Trading of Quotient
A number of hedge funds and other institutional investors have recently bought and sold shares of QTNT. ProShare Advisors LLC increased its stake in Quotient by 70.5% in the fourth quarter. ProShare Advisors LLC now owns 17,142 shares of the company's stock worth $45,000 after purchasing an additional 7,086 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Quotient during the first quarter valued at $48,000. Millennium Management LLC purchased a new position in shares of Quotient during the second quarter valued at $343,000. Walleye Capital LLC increased its stake in shares of Quotient by 246.3% during the fourth quarter. Walleye Capital LLC now owns 192,730 shares of the company's stock valued at $499,000 after buying an additional 137,071 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Quotient by 9,156.7% during the second quarter. JPMorgan Chase & Co. now owns 3,491,154 shares of the company's stock valued at $838,000 after buying an additional 3,453,439 shares during the period. Hedge funds and other institutional investors own 86.84% of the company's stock.
Quotient Company Profile
(Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.
Recommended Stories
- Get a free copy of the StockNews.com research report on Quotient (QTNT)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.
